Author:
Vorvul A. O.,Bobyntsev I. I.,Svishcheva M. V.,Medvedeva O. A.,Mukhina A. Yu.,Andreeva L. A.
Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. N. G. Levitskaya and A. A. Kamenskii, “The melanocortin system” Usp. Fiziol. Nauk., 40, No. 1, 44–65 (2009).
2. A. Catania, S. Gatti, G. Colombo, and J. M. Lipton, “Targeting melanocortin receptors as a novel strategy to control inflammation,” Pharmacol. Rev., 56, No. 1, 1–29 (2004), https://doi.org/https://doi.org/10.1124/pr.56.1.115001661.
3. S. V. Koroleva and N. F. Myasoedov, “Semax as a universal drug for therapy and research,” Biol. Bull., 45, No. 6, 589–600 (2018), https://doi.org/https://doi.org/10.1134/S000233291806005X.
4. D. A. Vilenskii, N. G. Levitskaya, L. A. Andreeva, et al., “Effects of chronic Semax administration on exploratory activity and emotional state in white rats,” Ros. Fiziol. Zh., 93, No. 6, 661–669 (2007).
5. K. A. Yatsenko, N. Y. Glazova, L. S. Inozemtseva, et al., “Heptapeptide Semax attenuates the effects of chronic unpredictable stress in rats,” Dokl. Biol. Sci., 453, 353–357 (2013), https://doi.org/https://doi.org/10.1134/S0012496613060161.